Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
Clinical Trials Related to NRG Oncology
Related studies linked through entity extraction aliases.
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Status
- RECRUITING
- Phase
- PHASE3
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
- Status
- RECRUITING
- Phase
- PHASE3
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
- Status
- RECRUITING
- Phase
- NA
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
- Status
- SUSPENDED
- Phase
- PHASE2/PHASE3
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3